Psychiatry and Neurology, Neurology · San Diego, CA
NPI
1538320395
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
200 W Arbor Dr
San Diego, CA, 92103
Phone (800) 926-8273
Groups this clinician bills Medicare through
Medicare paid, 2024
$36K
318 services
Medicare patients, 2024
142
Average age 67
Drug cost, 2024
$1.3M
159 prescriptions
Company payments, 2025
$188K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Chamindra G Laverty was code 99215 (office e&m - established), 75 times for 56 patients. In total Chamindra G Laverty billed 318 services in 20 codes, and Medicare paid $36K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 75 | 56 | $145.47 | $11K |
| 95886 Electrical Nerve Conductivity | Office | 52 | 40 | $77.80 | $4,046 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 41 | 23 | $25.90 | $1,062 |
| 99233 Hospital E&M - Subsequent | Facility | 36 | 14 | $96.25 | $3,465 |
| 99223 Hospital E&M - Initial | Facility | 32 | 29 | $140.60 | $4,499 |
| 95913 Electrical Nerve Conductivity | Office | 20 | 20 | $218.35 | $4,367 |
By year: 2022 $41K for 331 services; 2023 $27K for 212 services; 2024 $36K for 318 services.
Medicare prescription drug claims, 2024
In 2024, the drug Chamindra G Laverty prescribed most often to Medicare patients was Emflaza (Deflazacort), with 39 prescriptions and refills. In total Chamindra G Laverty wrote 159 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Emflaza Deflazacort | 39 | 39 | Under 11 | $267K |
| Pyridostigmine Bromide Generic | 26 | 30 | Under 11 | $1,846 |
| Gabapentin Generic | 15 | 25 | Under 11 | $250 |
| Evrysdi Risdiplam | 13 | 13 | Under 11 | $342K |
| Azathioprine Generic | 12 | 20 | Under 11 | $1,737 |
| Skyclarys Omaveloxolone | 11 | 11 | Under 11 | $343K |
| Armodafinil Generic | 11 | 11 | Under 11 | $219 |
Brand drugs: 69 claims; generic drugs: 90 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Chamindra G Laverty $188K ($185K in general payments such as food, travel and fees and $3,231 for research) from 7 companies. The largest payer was Sarepta Therapeutics, Inc. with $163K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.